Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report.
A 68-year-old man presented with gross hematuria. A papillary urethral tumor adjacent to the verumontanum was found by cystourethroscopy. Serum prostate-specific antigen (PSA) was 3.246 ng/ml. A transurethral biopsy specimen was most suggestive of a primary urothelial carcinoma of the prostate, for which a radical cystoprostatectomy was performed. The final pathology was prostatic ductal adenocarcinoma with very focal acinar features (Gleason score 5 %plus; 4 = 9, pT3bN0M0). Local recurrence and pelvic bone metastases developed 17 months later, and his PSA rose to 10.806 ng/ml. He was treated with combined androgen blockade and radiation. Two years later, the lesion showed progressive growth. Treatment followed with docetaxel (70 mg/m(2) every 3 weeks) and prednisolone 5 mg twice daily. After 10 cycles of chemotherapy, all lesions disappeared and PSA decreased to <0.005 ng/ml. Three years after chemotherapy, he maintains a complete response without any additional treatments. Docetaxel chemotherapy can be an effective treatment for patients with recurrent prostatic ductal adenocarcinoma.
Department of Urology, Shiga University of Medical Science, Otsu, Japan.
Ryo
R
Fujiwara
Department of Urology, Shiga University of Medical Science, Otsu, Japan.
Susumu
S
Kageyama
Department of Urology, Shiga University of Medical Science, Otsu, Japan.
Keiji
K
Tomita
Department of Urology, Shiga University of Medical Science, Otsu, Japan.
Eiki
E
Hanada
Department of Urology, Shiga University of Medical Science, Otsu, Japan.
Teruhiko
T
Tsuru
Department of Urology, Shiga University of Medical Science, Otsu, Japan.
Tetsuya
T
Yoshida
Department of Urology, Shiga University of Medical Science, Otsu, Japan.
Mitsuhiro
M
Narita
Central Research Laboratory, Shiga University of Medical Science, Otsu, Japan.
Takahiro
T
Isono
Department of Urology, Shiga University of Medical Science, Otsu, Japan.
Akihiro
A
Kawauchi
Chemotherapy; Docetaxel; Prostatic ductal adenocarcinoma